We screen first
(-)-epicatechin, a natural flavonoid compound, protects astrocytes against hemoglobin toxicity via nrf2 and AP-1 signaling pathways
Clinical trials are ongoing, and Novo Nordisk has indicated plans to file for approval
The combination of the very high price of these drugs typically about $1,000 per month per patient plus a relatively large number of patients who may benefit from them can result in a substantial net new cost to a health plan, potentially more than many employers or the employees who share the cost of coverage can afford
Methylenetetrahydrofolate Reductase C677T (Rs1801133) Polymorphism Is Associated with Bladder Cancer in Asian Population: Epigenetic Meta-Analysis as Precision Medicine Approach
It is a driver of multiple co-morbidities such as type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), hypertension, hypercholesterolaemia, cardiovascular disease and cancer (1)